Reflux disease and Barrett’s esophagus

Introduction

Digestive Disease Week (DDW) 2011 took place in Chicago, Illinois, USA (7 – 10 May), and featured several important presentations devoted to the endoscopic diagnosis and treatment of Barrett’s esophagus and gastroesophageal reflux disease (GERD). This review focuses on presentations from the plenary sessions, as well as on multicenter studies, meta-analyses, and new concepts presented at the meeting.

• References

• 1 Wallace MB, Saunders MD, Lovat L et al. Multicenter, randomized controlled trial of confocal laser endomicroscopy assessment of residual neoplasia after mucosal ablation or resection of gastrointestinal neoplasia in Barrett’s esophagus (CLEAN MARGIN-BE) – preliminary report. Gastrointest Endosc 2011; 73: 208
• 2 Herrero LA, Curvers WL, Bisschops R et al. Can endoscopy with narrow-band imaging reliably predict the presence of residual intestinal metaplasia at the neosquamocolumnar junction after radiofrequency ablation of Barrett’s esophagus?. Gatrointest Endosc 2011; 73: 376
• 3 Prasad G, Dunagan K, Tian J et al. Recurrence of intestinal metaplasia following radiofrequency ablation: rates and predictors. Gastrointest Endosc 2011; 73: 145-146
• 4 Shaheen N, Wang K, Wolfsen H et al. Durability of reversion to neosquamous epithelium following radiofrequency ablation for dysplastic BE: long term follow-up of the AIM Dysplasia trial. Gastroenterology 2011; 140: 1-179
• 5 Phoa K, Pouw R, van Vilsteren F et al. Radiofrequency ablation +/– endoscopic resection for Barrett’s esophagus with high-grade dysplasia and/or early cancer: durability of the post-treatment neosquamous epithelium at 5-year follow-up. Gastrointest Endosc 2011; 73: 198
• 6 Pech O, May A, Manner A et al. Endoscopic resection in 953 patients with mucosal Barrett’s cancer. Gastrointest Endosc 2011; 73: 146
• 7 Krishnamoorthy R, Ragunath K, Thomas T. Efficacy and safety of extensive endomucosal resection for complete Barrett’s eradication in early Barrett’s neoplasia: a meta-analysis. Gastrointest Endosc 2011; 73: 200
• 8 van Vilsteren F, Pouw R, Alvarez HerreroL et al. The learning curve of endoscopic resection of esophageal neoplasia is associated with significant complications even in a structured training program. Gastrointest Endosc 2011; 73: 398
• 9 Bulsiewicz W, Pasricha S, Dellon E et al. The effect of operator experience on treatment of dysplastic Barrett’s esophagus with radiofrequency ablation. Gastroenterology 2011; 140: 211
• 10 van Vilsteren F, Alvarez Herrero L, Pouw R et al. Combined radiofrequency ablation and endoscopic resection in a single treatment session for Barrett’s esophagus containing high-grade dysplasia or early cancer: a feasibility study of a “single-step” treatment regimen. Gastrointest Endosc 2011; 73: 202
• 11 Amin A, Samala N, Desai T. The incidence of esophageal adenocarcinoma in Barrett’s esophagus (BE) low grade dysplasia (LGD) is 1 to 1 9% annually and may be a fraction of non-esophageal mortality: a meta-analysis of 40 studies. . Gastroenterology 2011; 140: 223
• 12 Wani S, Lieberman D, Gavini H et al. Is the extent of low-grade dysplasia (LGD) in Barrett’s esophagus (BE) a risk factor for the development of esophageal adenocarcinoma (EAC): results from a large, multicenter cohort study. Gastroenterology 2011; 140: 217
• 13 Verbeek R, van Oijen M, tenKate F et al. Risk factors for prevalent adenocarcinomas in patients with high-grade dysplasia in Barrett’s esophagus: a Dutch population-based study. Gastroenterology 2011; 140: 667
• 14 Wani S, Edmundowicz S, Abrams J et al. Accuracy of endoscopic ultrasonography (EUS) in staging early neoplasia in Barrett’s esophagus (BE): results from a large multicenter cohort study. Gastrointest Endosc 2011; 73: 166-167
• 15 Panossian AM, Crespo S, DeMelo S et al. Does EUS have a role in the evaluation of Barrett’s high grade dysplasia before endoscopic treatment?. Gastrointest Endosc 2011; 73: 16
• 16 Bulsiewicz W, Rogers A, Dellon E et al. The clinical utility of endoscopic ultrasound before ablation in patients with Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 2011; 73: 209
• 17 Goutte M, Slaughter J, Garrett C et al. What does impedance monitoring on PPI therapy tell us?. Gastroenterology 2011; 140: 43
• 18 Hershcovici T, Jha L, Cui H et al. Comparison of the degree of nighttime duodenogastroesophageal (DGER) and acid reflux between patients who failed and those who were successfully treated with a proton pump inhibitor (PPI) once daily. Gastroenterology 2011; 140: 43
• 19 Shukla S, Guha S. Cardiovascular implications of proton pump inhibitors and clopidogrel interaction: a meta-analysis of randomized controlled trials. Gastroenterology 2011; 140: 79
• 20 Liu H, Waxman D, Main R et al. Trends in cost and utilization of anesthesia services during gastroenterology procedures in 2003–2009. Gastroenterology 2011; 140: 205-206